Week in Review: The latest from PhRMA

Priscilla VanderVeer
Priscilla VanderVeer March 4, 2016

Week in Review: The latest from PhRMA.

Share This

week-in-review.jpgCommunications with health care professionalsA new paper from the Duke-Margolis Center for Health Policy rightly makes the argument in favor of establishing a more effective regulatory framework for communications between biopharmaceutical companies and health care professionals. Learn more about the importance of identifying solutions that provide physicians and patients with up-to-date information.

Protecting intellectual property – Biopharmaceutical innovators bring valuable new medicines to patients who need them around the world. To help protect this innovation, we participated in a public hearing that will inform the federal government’s annual “Special 301” review of overseas practices that deny adequate and effective intellectual property protection.  Read more about our policies for addressing intellectual property and market access barriers abroad

Biopharmaceutical innovation – New therapies called antibody drug conjugates, or ADCs, currently under investigation by  research-based biopharmaceutical manufacturers show great promise in targeting and attacking tumors when used in combination with current therapies, such as chemotherapy.  Learn more about what Pfizer’s Senior Vice president & Group Leader for Oncology, Dr. Robert Abraham, describes as “precision weapons against cancer.”

50 years of PhRMA Foundation – The PhRMA Foundation is celebrating 50 years of operation and we’re highlighting five key facts about its work to support young pharmaceutical scientists across the United States.

Medicare Monday – As part of our then-and-now series, we took a look at costs for Medicare Part D over the past 10 years. What we found is that spending for the Part D program has remained lower than initial projections and premiums have remained stable.